Log in to search using one of your social media accounts:

 

Hemovent expands Series A

Hemovent said today it received an undisclosed amount of funding as part of an oversubscribed Series A expansion round. The funds came from all existing investors, the Aachen, Germany-based company said, as well as newly invested 1st Capital Partner. Hemovent said that the funding comes shortly after it completed the 1st series of in vivo trials of its artificial lung technology platform which it is developing for a range of indications including extracorporeal CO2 removal and extracorporeal life support. “The fact that all Hemovent investors participated in this new round, and that 1st Capital Partner is an experienced life sciences investment firm known for investing sizable funds in both early-stage and follow-on rounds, bears strong testimony to the opportunity ahead of us as well as the efficient progress we have been able to make to date. Our investors understand Hemovent’s platform is positioned to disrupt a billion-dollar market. In vivo trials have already validated our platform’s superior blood-handling behavior and efficiency parameters compared to standard ECMO. We expect when Hemovent is available by mid-next year it will immediately drive ECMO usage not only for ECLS but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” CEO Christof Lenz said in a prepared statement. Last February, Hemovent said it raised $6m in a Series A round to support its portable extra corporeal membrane oxygenat...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory Hemovent Source Type: news

Related Links:

Authors: Matsumoto K, Yamasaki N, Tsuchiya T, Miyazaki T, Kamohara R, Hatachi G, Tanigawa K, Eishi K, Nagayasu T Abstract The number of patients who need cardiac support with a left ventricular assist device (LVAD) has increased over the last decade. However, the number of reports of organ retrieval from donors with an LVAD is still small. Successful lung retrieval for single lung transplantation was performed from a donor on LVAD support. This required special care not to injure the heart, great vessels, and the device, particularly the outflow conduit, because of significant conglutination around the device. A ri...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Thabut G, Mal H Abstract With more than 50,000 procedures having been performed worldwide, lung transplantation (LT) has become the standard of care for patients with end-stage chronic respiratory failure. LT leads to dramatic improvements in both pulmonary function and health related quality of life. Survival after LTs has steadily improved, but still lags far behind that observed after other solid organ transplantations, as evidenced by a median survival rate that currently stands at 5.8 years. Because of these disappointing results, the ability of LT to expand survival has been questioned. However, the ...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Benden C Abstract Pediatric lung transplantation has been undertaken since the 1980s, and it is today considered an accepted therapy option in carefully selected children with end-stage pulmonary diseases, providing carefully selected children a net survival benefit and improved health-related quality of life. Nowadays,>100 pediatric lung transplants are done worldwide every year. Here, specific pediatric aspects of lung transplantation are reviewed such as the surgical challenge, effects of immunosuppression on the developing pediatric immune system, and typical infections of childhood, as it is vital ...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Gottlieb J Abstract Shortage of donor lungs in most western countries and broadening of indications for lung transplantation (LTx) has led increased waiting list mortality in the past. Usually donor lungs and recipients are matched by size as measured by total lung capacity and blood type in first order. In some countries regional allocation comes first, in other countries a national wait list exists and some nations are organized in supranational allocation systems. Organ distribution should respect the ethical principles of equity, justice, beneficence and utility. Generally, top priority on the list sho...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Inci I Abstract The number of patients actively awaiting lung transplantation (LTx) is more than the number of suitable donor lungs. The percentage of lung retrieval rate is lower when compared to other solid organs. The use of lungs from donation after cardiocirculatory death (DCD) donors is one of the options to avoid organ shortage in LTx. After extensive experimental research, clinical application of DCD donation is becoming wider. The results from most of the centers show at least equal survival rate compared to donors from brain death. This review paper will summarize experimental background and clin...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM Abstract Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lung transplantation. Given the clinical heterogeneity of CLAD, recently two phenotypes of CLAD have been defined [bronchiolitis obliterans syndrome (BOS) vs. restrictive allograft syndrome (RAS) or restrictive CLAD (rCLAD)]. BOS is characterized by an obstructive pulmonary function, air trapping on CT and obliterative bronchiolitis (OB) on histopathology, while RAS/rCLAD patients show a restrictive pulmonary function, persistent pleuro-parenchymal inf...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Kloth C, Thaiss WM, Hetzel J, Bier G, Wirths S, Nikolaou K, Horger M Abstract BACKGROUND: To quantify lung parenchymal changes in symptomatic patients with chronic pulmonary graft-versus-host disease 3 years after allogeneic stem cell transplantation (allo-SCT) by means of CT-densitometry (CTD) and to compare results with those of established pulmonary function tests (PFT). METHODS: The study group consisted of 26 patients with pulmonary cGvHD (19 males, 7 females; mean age, 49.29±15.89; range, 19-72 years). The diagnosis was based on clinical symptoms, PFT and chest-CT findings. CTD and PFT wer...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
More News: Funding | Germany Health | Lung Transplant | Respiratory Medicine